Hansa Biopharma AB (publ)

Stockholm Stock Exchange:HNSA.ST

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

Sweden

Market Cap

USD 166.58 M

Share Price

USD 2.54

Avg Daily Volume

163,653

Change (1 day)

1.66%

Change (1 year)

-42.53%

Change (YTD)

-28.27%

Hansa Biopharma AB (publ) Net Income Margin for the year ending December 31, 2024: -471.20%

Hansa Biopharma AB (publ) Net Income Margin is -471.20% for the year ending December 31, 2024, a -24.03% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Hansa Biopharma AB (publ) Net Income Margin for the year ending December 31, 2023 was -620.25%, a 56.83% change year over year.
Hansa Biopharma AB (publ) Net Income Margin for the year ending December 31, 2022 was -395.49%, a -75.56% change year over year.
Hansa Biopharma AB (publ) Net Income Margin for the year ending December 31, 2021 was -1,618.40%, a -76.55% change year over year.
Hansa Biopharma AB (publ) Net Income Margin for the year ending December 31, 2020 was -6,901.49%, a -35.51% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Income Margin	EBT Margin	Operating Income Margin	Gross Profit Margin

Stockholm Stock Exchange: HNSA.ST

Hansa Biopharma AB (publ)

CEO	Ms. Renee Aguiar-Lucander
IPO Date	Oct. 17, 2007
Location	Sweden
Headquarters	PO Box 785
Employees	138
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.